Abstract
Aims
Gestational diabetes mellitus (GDM) is the most common metabolic disorder of pregnancy. The aim of the study is to compare the effect of different dosages of inositol stereoisomers supplementation on insulin resistance levels and several maternal-fetal outcomes in GDM women.
Methods
Participants were randomly allocated to receive daily: 400 mcg folic acid (control treatment), 4000 mg myo-inositol plus 400 mcg folic acid (MI treatment), 500 mg d-chiro-inositol plus 400 mcg folic acid (DCI treatment) or 1100/27.6 mg myo/d-chiro-inositol plus 400 mcg folic acid (MI plus DCI treatment). The homeostasis model assessment of insulin resistance (HOMA-IR) was measured at the diagnosis of GDM and after 8 weeks of treatment. Secondary outcomes, obstetric outcomes and any maternal or fetal complication at delivery were also collected.
Results
Eighty GDM women were assigned to one of the four arms of study (20 per arm). A significant delta decrease in HOMA-IR index was found in subjects of MI group without insulin therapy compared to control group (p < 0.001). A lower variation in average weight gain (at delivery vs pre-pregnancy and OGTT period) was detected in MI group vs control group (p = 0.001 and p = 0.019, respectively). Moreover, women exposed to MI and MI plus DCI required a significantly lower necessity of an intensified insulin treatment. Women of the control group had newborns with higher birth weight compared with women treated with inositol (p = 0.032).
Conclusions
Our study provides interesting but preliminary results about the potential role of inositol stereoisomers supplementation in the treatment of GDM on insulin resistance levels and several maternal-fetal outcomes. Further studies are required to examine the optimal and effective dosages of different inositol supplements.
Clinical trial reg. no.
NCT02097069, ClinicalTrial.gov.
Similar content being viewed by others
Abbreviations
- GDM:
-
Gestational diabetes mellitus
- MI:
-
Myo-inositol
- DCI:
-
d-Chiro-inositol
- HOMA-IR:
-
Homeostatic model assessment of insulin resistance
References
American Diabetes Association (ADA) (2018) Standards of Medical Care in Diabetes-2018. Diabetes Care 41(Suppl 1):S13–S27
Di Cianni G, Miccoli R, Volpe L, Lencioni C, Del Prato S (2003) Intermediate metabolism in normal pregnancy and in gestational diabetes. Diabetes Metab Res Rev 19(4):259–270
Chiefari E, Arcidiacono B, Foti D, Brunetti A (2017) Gestational diabetes mellitus: an updated overview. J Endocrinol Investig 40(9):899–909
Casey BM, Lucas MJ, Mcintire DD, Leveno KJ (1997) Pregnancy outcomes in women with gestational diabetes compared with the general obstetric population. Obstet Gynecol 90(6):869–873
Jovanovic L, Pettitt DJ (2001) Gestational diabetes mellitus. JAMA 286(20):2516–2518
Croze ML, Soulage CO (2013) Potential role and therapeutic interests of myo-inositol in metabolic diseases. Biochimie 95(10):1811–1827
Nestler JE, Jakubowicz DJ, Reamer P, Gunn RD, Allan G (1999) Ovulatory and metabolic effects of d-chiro-inositol in the polycystic ovary syndrome. N Engl J Med 340(17):1314–1320
Murphy A, Shamshirsaz A, Markovic D, Ostlund R, Koos B (2016) Urinary excretion of myo-inositol and d-chiro-inositol in early pregnancy is enhanced in gravidas with gestational diabetes mellitus. Reprod Sci 23(3):365–371
Matarrelli B, Vitacolonna E, D’Angelo M et al (2013) Effect of dietary myoinositol supplementation in pregnancy on the incidence of maternal gestational diabetes mellitus and fetal outcomes: a randomized controlled trial. J Matern Fetal Neonatal Med 26(10):967–972
D’Anna R, Scilipoti A, Giordano D et al (2013) Myo-inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes. Diabetes Care 36(4):854–857
D’Anna R, Di Benedetto A, Scilipoti A et al (2015) Myo-inositol supplementation for prevention of gestational diabetes in obese pregnant women. Obstet Gynecol 126(2):310–315
Santamaria A, Di Benedetto A, Petrella E et al (2016) Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial. J Matern Fetal Neonatal Med 29(19):3234–3237
Farren M, Daly N, McKeating A, Kinsley B, Turner MJ, Daly S (2017) The prevention of gestational diabetes mellitus with antenatal oral inositol supplementation: a randomized controlled trial. Diabetes Care 40(6):759–763
Malvasi A, Kosmas I, Mynbaev OA et al (2017) Can trans resveratrol plus d-chiro-inositol and myo-inositol improve maternal metabolic profile in overweight pregnant patients? Clin Ter 168(4):e240–e247
Corrado F, D’Anna R, Di Vieste G et al (2011) The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes. Diabet Med 28(8):972–975
Di Biase ND, Martinelli M, Florio V, Meldolesi C, Bonito M (2017) The effectiveness of d-chiro inositol treatment in gestational diabetes. Diabetes Case Rep 2:131
Maurizi AR, Menduni M, Del Toro R et al (2017) A pilot study of d-chiro-inositol plus folic acid in overweight patients with type 1 diabetes. Acta Diabetol 54(4):361–365
International Association of Diabetes and Pregnancy Study Groups Consensus Panel, Metzger BE, Gabbe SG et al (2010) International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care 33(3):676–682
ACOG. Committee opinion (2002) Number 267, January 2002: exercise during pregnancy and the postpartum period. Obstet Gynecol 99:171–173
Bertolotto A, Lencioni C, Volpe L, Di Cianni G (2007) Rassegna “Attività fisica e diabete gestazionale”. G It Diabetol Metab 27:75–81
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28(7):412–419
Galtier-Dereure F, Boegner C, Bringer J (2000) Obesity and pregnancy: complications and cost. Am J Clin Nutr 71(Suppl. 5):1242S–1248S
Celentano C, Matarrelli B, Mattei PA, Pavone G, Vitacolonna E, Liberati M (2016) Myo-inositol supplementation to prevent gestational diabetes mellitus. Curr Diab Rep 16(3):30 (Review)
Huvinen E, Eriksson JG, Koivusalo SB et al (2018) Heterogeneity of gestational diabetes (GDM) and long-term risk of diabetes and metabolic syndrome: findings from the RADIEL study follow-up. Acta Diabetol. https://doi.org/10.1007/s00592-018-1118-y
Benelli E, Del Ghianda S, Di Cosmo C, Tonacchera M (2016) A combined therapy with myo-inositol and d-chiro-inositol improves endocrine parameters and insulin resistance in PCOS young overweight women. Int J Endocrinol 2016:3204083
Iuorno MJ, Jakubowicz DJ, Baillargeon JP et al (2002) Effects of d-chiro-inositol in lean women with the polycystic ovary syndrome. Endocr Pract 8(6):417–423
Di Biase N, Balducci S, Lencioni C et al (2017) Attività fisica nella gravidanza di donne con diabete. “Il Diabete” 29(2):209–222
Di Biase N, Balducci S, Lencioni C et al (2017) Attività fisica nella gravidanza di donne con diabete, Physical activity in pregnant women with diabetes JAMD 20(1):44–54
Handelsman Y, Mechanick JI, Blonde L et al; American Association of Clinical Endocrinologists (2011) Medical guidelines for clinical practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract 17(Suppl 2):1–53
American Diabetes Association (2011) Standards of medical care in diabetes 2011. Diabetes Care 34(Suppl 1):S11–S61
Kopec JA, Ogonowski J, Rahman MM, Miazgowski T (2015) Patient-reported outcomes in women with gestational diabetes: a longitudinal study. Int J Behav Med 22(2):206–213
Farrar D, Simmonds M, Griffin S et al (2016) The identification and treatment of women with hyperglycaemia in pregnancy: an analysis of individual participant data, systematic reviews, meta-analyses and an economic evaluation. Health Technol Assess 20(86):1–348
Brown J, Crawford TJ, Alsweiler J, Crowther CA (2016) Dietary supplementation with myo-inositol in women during pregnancy for treating gestational diabetes. Cochrane Database Syst Rev 9:CD012048
Acknowledgements
The authors wish to thank Lucrezia Gasparini for the contribution and all women who participated in this study.
Funding
This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors.
Author information
Authors and Affiliations
Contributions
The study was designed by EV, CC, BP, and GDV. CC and ML contributed to clinical evaluation and support to the recruitment of patients. FF contributed to data acquisition, analysis, and interpretation. The manuscript was drafted by FF, MF, and EV. MDN and IZ were the statisticians that performed and supervised the statistical analyses; they also helped in the drafting and editing of the manuscript. CC, FF, BP, GDV, MDN, and MF contributed to the reviewed of the manuscript. All authors were involved in critical revision and approved the final version of the manuscript before submission. EV and MDN are the guarantor of this work and, as such, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical standard statement
The study was in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments.
Informed consent
Informed consent was obtained from the patients included in the study.
Additional information
Managed By Massimo Federici.
Rights and permissions
About this article
Cite this article
Fraticelli, F., Celentano, C., Zecca, I.A. et al. Effect of inositol stereoisomers at different dosages in gestational diabetes: an open-label, parallel, randomized controlled trial. Acta Diabetol 55, 805–812 (2018). https://doi.org/10.1007/s00592-018-1157-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00592-018-1157-4